Index 1993

Subject

ACBE report, 105(NR)
Acid rain, 1020(NR)
Acost, government response, 105(NR)
Adhesion, 892(B)
Adhesives, 273(TP)
AECI-Sasol merger, 662(NR)
AFRC,
  annual report, 16(NR)
  corporate plan, 284(NR)
Agricultural research, 755
Agriculture, cleaner, 855(NR)
Aids research, 462(P), 465(NR)
Akzo, Nobel merger, 1015(NR)
Akzo Fibres profits, 380(NR)
Alkali Act, 684, 866(L)
Alkanes and cycloalkanes, 611(B)
Allen, Peter, 184(NR)
Allied Colloids,
  HSE prosecution, 183(NR)
  NRA prosecution, 739(NR)
Alpha trial results, 20(NR)
Alternative fuels, 374(P)
Aluminium in food, 180(P)
Aluminium, 573(L)
Analytical training, 949(C), 1030(L)
Animal tests, 472(NR)
alternatives, 917(TP)
Antarctic expedition, 551(TP)
Anthocyanin pigments, 875
Arnold, Dennis A., 70(O)
Ashby, Eric, 340(O)
Assessment, practical, 299(C)
Associated Octel, new plant, 187(NR)
Atmospheric pollution, 883
Ayscough, Peter Brian, 626(O)
AZT,
  trial results, 381(NR), 739(NR)
  restrictions, 664(NR)

Bader, Alfred, 919(TP)
Barr, ICI settlement, 285(NR)
BASF,
  profits, 16(NR), 379(NR), 51(NR)
  ICI exchange, 185(NR)
Bayer
  profits, 16(NR), 379(NR), 51(NR)
  tradename injunction, 20(NR)
BBG, new drugs, 664(NR)
Bell, Frank, 152(O)
Benzene exposure, 456(TP)
Benzene structure, 126, 401(C), 396(L), 675(L)
Beta-damascenone, 923(P)
Bioethics convention, 290(NR)
Bioinsecticide, 105(NR)
Biosensors, 612(B)
BioSPECS, profile, 1022(NR)
Biosurfactants, 1059(B)
Biotech draft directive, 108(NR)
Biotechnology, 468(NR), 663(NR), 927(NR), 1016(NR)
Biotechnology forum, 385(NR), 928(NR)
Bird, toxic, 12(P)
Bisset, Norman Grainger, 816(O)
Blood liquefaction, 116(L), 296(L)
BOC,
  new gas plant, 559(NR)
  profile, 840(TP)
BP, Bitor sale, 1021(NR)
BP Chemicals,
  job cuts, 281(NR)
  plant closure, 184(NR)
BP Nutrition sell-offs, 662(NR)
British Association meeting, 841(TP)
British Technology group, 1017(NR), 1018(NR)
Business in Europe, 190(NR)

Cahn, R. W., articles, 695(B)
Calgon sale, 662(NR)
Cancer drug, 847(P)
Cannizzaro, 140(B)
Cantab, flotation, 854(NR)
Carbohydrate fuels, 28(L), 198(L), 296(L), 674(L)
Carbohydrates, 696(B)
Carbon allotropes, 297(L), 574(NR)
Carbon nitride, 848(P)
Carbon tetrachloride, 28(L)
Carcinogenesis, 425(B)
Carcinogens, 100(TP), 240(B)
Castleford incident, 15(NR)
Caustic soda, 368(TP)
CBI,
  innovations report, 183(NR)
  white paper comment, 742(NR)
CD-ROM, organic compounds, 976(B)
Cefic assembly, 661(NR)
Celltech,
  Hoffman-La Roche deal, 930(NR)
  share sale, 1016(NR)
Centocor, Wellcome alliance, 930(NR)
CFC control, 18(NR), 741(NR)
Chaos, 611(B), 804(B)
Chatterji, Deb, 840(TP)
Chemac report, 949(C), 1030(L)
Chemical bonds, 328(B)
Chemical delivery systems, 462(P)
Chemical production figures, 852(NR)
Chemical weapons, 584
Chemical Weapons Convention, 103(NR), 283(NR)
Chemistry in Britain, Sept cover, 1029(L)
Chemistry sets, 1005(TP)
China, toxic waste riots, 928(NR)
Chinese herbal drugs, 140(B)
Chinese medicine, 838(TP), 1030(L)
Chiral synthesis, 973(B), 974(B), 1053
Chlorine, 5(TP)
CIA,
  biotechnology forum, 928(NR)
  chemical business outlook, 103(NR)
  health and safety, 398(L)
  Investment conference, 383(NR)
  investment survey, 379(NR)
  responsible care, 269(TP)
  Socsa formation, 468(NR)
Ciba,
  Grimsby site, 661(NR)
  profits, 470(NR), 854(NR)
Cindu chemicals, naphthalene plant, 465(NR)
Climate modelling, 696(B)
Clinical biochemistry, 312, 573(L)
Clinton administration, 176(TP)
CO as messenger molecule, 556(P)
CO_2 fixation, 297(L)
CO_2 emissions, 180(P), 190(NR), 385(NR), 467(NR), 670(NR)
Coalite, NRA action, 18(NR)
Coatings, 892(B)
Combustion at surfaces, 34
Composites, 12(P)
Computer designed chemicals, 460(P)
Computerised control, 385(NR)
Computing for scientists, 804(B)
Conducting polymers, 967
Contaminated land, 959
Control of chemicals, 802(B)
Coordination chemistry, 973(B)
Copper biochemistry, 695(B)
COSHH amendment, 109(NR)
Courtaulds,
  Hoechst fibres deal, 560(NR)
  profile, 8(TP)
Croatia, pollution, 185(NR)
Croda Kerr, Monnex purchase, 283(NR)
Crown ethers, 974(B)
Crystallography, 892(B)
Cyanobacteria, 278(P)
Cyclodextrins, 28(L)
Cyclops, 187(NR)
Cytec spin-off, 927(NR)

Dambusters, 728(TP)
Danish HCFC bans, 1020(NR)
Data protection, 691
Davis, David, 1007(TP)
Degradable plastics, 178(P), 466(NR)
Degree courses, 129
Diabetes treatment, 98(TP)
Dilatant colloids, 731(P), 1030(L)
Dioxins, 140(B), 198(L)
Distance learning, 768
Djerassi, C., autobiography, 695(B)
DNA mismatches, 484
DNA profiling, 178(P), 419
DNA sequence alteration, 202
Dow Chemical
  new thermoplastics, 462(P)
  reorganisation, 104(NR)
Drilling mud, 383(NR)
Drug crime prevention, 415
Drug delivery, 10(P)
Drug licensing, 472(NR)
Drug prices, 665(NR)
Drug trade legislation, 20(NR)
Drugs, natural 327(B)
Drugs, controlled delivery, 425(B)
DTI,
  innovations report, 183(NR)
  SAIS scheme, 383(NR)
DuPont Nylon job losses, 927(NR)
DuPont, plant purchase, 104(NR)
Dyes, 611(B)

Eastman-Kodak split, 661(NR), 852(NR)
EC environment policy, 290(NR), 1020(NR)
EC legislation, 17(NR)
ECMRA, Madrid, 1009(TP)
ECO survey, 108(NR)
Economy, 851(NR)
Ecotoxicology, 1059(B)
Education, 837(TP), 1029(L), 1018(NR)
EELS, 41
Electrochemistry, 1059(B)
Electronic data, 274(TP)
Electronic mail, 28(L)
Electron surface scattering, 41
Elf Sanofi, YSL merger, 183(NR)
Eli Lilly, job cuts, 1019(NR)
Employment in France, 95(TP), 396(L)
EMS-Dottikon explosion, 740(NR)
Energy programmes, EC, 744(NR)
Energy resources, 518(B)
English China Clays, Calgon purchase, 662(NR)
Enimont break-up, 738(NR)
Environment,
  agency, 21(NR)
  and industry, 695(B)
  EC policy, 290(NR), 1020(NR)
  government policy, 105(NR)
  World Industry Council, 928(NR)
Environment and Health Institute, 741(NR)
Environmental convention, 286(NR)
Enzymes in feedstuff, 936(NR)
European chemist registration, 752(L)
Exhaust emissions, 187(NR)
Expert witness fees, 866(L)
Explosion, fertiliser plant, 928(NR)

Faraday centres, 107(NR), 188(NR)
Fats in food, 482(L)
FDA drug approvals, 470(NR)
Feruzzi, rescue plan, 1015(NR)
Fine chemicals, 239(B)
Fire, 517(B)
Fireworks, 277(P)
Fisons,
  abandons Tipredane, 381(NR)
  new labs, 927(NR)
  profits, 852(NR)
  sell-offs, 20(NR), 104(NR)
  Tilade allegations, 1016(NR)
Flame-proofing regulations, 1020(NR)
Floral pigments, 875
Fluorine chemistry, 696(B)
Fluoropolymers, 10(P)
Flu virus inhibitor, 561(NR)
Food,
  additives, 384(NR), 743(NR)
  and cancer, 973(B)
  free radicals, 210
  irradiation, 674(L)
  legislation, 112(NR)
  safety, 140(B), 180(P)
  science, 242(B)
  taints, 1060(B)
Forensic registration, 482(L)
Forensic science,
  analysing evidence, 408
  conference, 463(P)
  DNA profiling, 419
  drug crime precention, 415
  forensic toxicology, 296(L), 405
  House of Lords report, 560(NR)
  inquiry, 283(NR), 465(NR)
  royal commission report, 662(NR)
  scanning electron microscopy, 413
  special issue, 405
Framework 4, 22(NR), 469(NR), 564(NR)
Framework funds, 108(NR)
Free radicals, 1012(P), 1060(B)
Free radicals in food, 210
Free radical reactions, 53(B)
FT-ICR/MS, 611(B)
Funding young researchers, 385(NR)

Gas hydrates, 375(P)
GEC Marconi Ga-As plant, 184(NR)
Genetically engineered synthesis, 687
Genetically modified organisms, 385(NR), 936(NR)
Giachardi, David, 8(TP)
Gibberelic acid, 463(P)
Glaxo,
  chairman resigns, 285(NR)
  FDA warning, 286(NR)
  OTC drugs, 186(NR)
  profits, 852(NR)
  reorganisation, 929(NR)
  SmithKline Beecham patent row, 20(NR), 470(NR)
  suit against Novopharm, 854(NR), 930(NR)
  Wellcome, Warner Lambert OTC link, 740(NR)
GNVQs, 729(TP)
Gold deposits, 734(P)
Government lab job cuts, 1018(NR)
Graduate recruitment, 93(TP), 853(NR)
Green, Michael, 705(O)
Greenpeace, ICI prosecution, 466(NR)

Halon bank, 287(NR)
Hanson Industries, buys Quantum Chemical, 663(NR)
Hazard, reaction, 481(L), 867(L)
Hazardous waste, 460(P)
HCFC phasing out, 666(NR), 1020(NR)
Health and safety, 28(L), 100(TP), 109(NR), 196(L), 328(B), 611(B), 677
  Irish review, 927(NR)
Herbal remedies, 178(P)
Herbicides, 425(B)
Hermaphrodite fish, 481(L), 674(L)
Heterocyclics, 54(B)
Hickson and Welch,
  Castleford report, 15(NR)
  fined, 739(NR)
  HSE prosecution, 465(NR)
Higher education, 299(C), 1018(NR)
History of chemistry, 53(B), 891(B)
History of science, 370(TP), 518(B), 801(B), 973(B)
Hoechst,
  accidents, 380(NR)
  Courtaulds fibres deal, 560(NR)
  profits, 16(NR), 379(NR), 851(NR)
  Schering deal, 559(NR), 737(NR)
  South America, 554(TP)
Hoffman-La Roche, Celltech deal, 930(NR)
Holliday Chemical Holdings,
  profits, 853(NR)
  share flotation, 282(NR)
Holt, Paul Frederic, 251(O)
Hormones in livestock, 290(NR), 564(NR), 743(NR)
Hünig's base, 1042
Huntsman Corporation, Texaco Chemical purchase, 851(NR)
Hutchinson, David, 437(O)
Hydrocarbon dendrimer, 460(P)

ICI,
  Barr, settlement, 285(NR)
  BASF exchange, 185(NR)
  electricity deal, 185(NR)
  Greenpeace prosecution, 466(NR)
  herbicide, 10(P)
  Monnex sale, 283(NR)
  Monsanto dispute, 17(NR)
  new fungicide, 17(NR)
  new subsidiary, 15(NR)
  profits, 468(NR), 737(NR), 1016(NR)
  Zeneca demerger, 104(NR), 281(NR), 470(NR)
Illuminated manuscripts, 118
Image,
  chemistry, 482(L), 945(L)
  industry, 379(NR)
  pharmaceuticals, 367(TP)
  science, 853(NR)
Immunosupressants, 659(P)
Inch, Tom, profile, 725(TP)
Incinerator, new ReChem, 18(NR)
Incinerators, planned, 18(NR)
Inclusion compounds, 132
Industrial chemistry,
  chiral synthesis, 1053
  drug process development, 1037
  Loop reactor process, 1050
  oxalyl chloride, 1046
  process development, 1035
  selective reagents, 1042
  special issue, 1035
Ingold, Christopher Kelk, 867(L), 880
Inorganic chemistry, 328(B)
Inorganic materials, 891(B)
Inorganic ring systems, 517(B)
Institut Merieux, Rhône-Poulenc merger, 930(NR)
Interstellar chemistry, 680
Ionic strength, 1033(C)
Irving, Harry, 982(O)

Japanese industry, 1018(NR)
Japanese research, 801(B)
Japanese science, 553(TP)
Jet fuels, 760, 947(L)

Kekulé, August, 126, 974(B)
Kirk, David Neville, 437(O)
Kodak-Eastman split, 661(NR), 852(NR)

Laboratory reports, 518(B)
Laevoglucosan, 278(P)
Lancaster Synthesis new site 184(NR)
Landowner Liquid Fertilisers, explosion, 928(NR)
Lawter Products, explosion, 853(NR)
Lecture-demonstrations, 656(TP), 868(L)
Leslie, May Sybil, 206, 573(L)
Lewis, David Thomas, 250(O)
Light, 425(B)
Limited list drugs, 186(NR)
Lipids, 696(B)
Liquid crystal polymers, 425(B)
Livestock fattening, 17(NR)
Llewelyn-Jones, prosecution, 559(NR)
Loop reactor process, 1050
Lorenzo's oil, 175(TP)
Loschmidt, Josef 126

Magic bullet, 770
Malaria drug, 923(P)
Manoplax,
  warning, 470(NR)
  withdrawn, 737(NR)
Marine sponge drug, 556(P)
Mass spectrometry, 54(B)
Materials science, 139(B)
Mechanisms, organic, 696(B)
Medco sale, 740(NR), 1019(NR)
Medeva,
  profits, 285(NR), 854(NR)
  Ribosepharm acquisition, 381(NR)
  shares fall, 738(NR), 1015(NR)
Media fellowships, 173(TP)
Medicinal chemistry, 974(B)
Medicine, natural, 327(B)
Medicines Information Bill, 186(NR), 285(NR), 465(NR)

Key

B—Book review
C—Controversies
L—Letter
NR—News review
O—Obituary
P—Perspective
TP—Talking point

Index 1993

Subject

ACBE report, 105(NR)
Acid rain, 1020(NR)
Acost, government response, 105(NR)
Adhesion, 892(B)
Adhesives, 273(TP)
AECI-Sasol merger, 662(NR)
AFRC,
  annual report, 16(NR)
  corporate plan, 284(NR)
Agricultural research, 755
Agriculture, cleaner, 855(NR)
Aids research, 462(P), 465(NR)
Akzo, Nobel merger, 1015(NR)
Akzo Fibres profits, 380(NR)
Alkali Act, 684, 866(L)
Alkanes and cycloalkanes, 611(B)
Allen, Peter, 184(NR)
Allied Colloids,
  HSE prosecution, 183(NR)
  NRA prosecution, 739(NR)
Alpha trial results, 20(NR)
Alternative fuels, 374(P)
Aluminium in food, 180(P)
Aluminium, 573(L)
Analytical training, 949(C), 1030(L)
Animal tests, 472(NR)
alternatives, 917(TP)
Antarctic expedition, 551(TP)
Anthocyanin pigments, 875
Arnold, Dennis A., 70(O)
Ashby, Eric, 340(O)
Assessment, practical, 299(C)
Associated Octel, new plant, 187(NR)
Atmospheric pollution, 883
Ayscough, Peter Brian, 626(O)
AZT,
  trial results, 381(NR), 739(NR)
  restrictions, 664(NR)

Bader, Alfred, 919(TP)
Barr, ICI settlement, 285(NR)
BASF,
  profits, 16(NR), 379(NR), 51(NR)
  ICI exchange, 185(NR)
Bayer
  profits, 16(NR), 379(NR), 51(NR)
  tradename injunction, 20(NR)
BBG, new drugs, 664(NR)
Bell, Frank, 152(O)
Benzene exposure, 456(TP)
Benzene structure, 126, 401(C), 396(L), 675(L)
Beta-damascenone, 923(P)
Bioethics convention, 290(NR)
Bioinsecticide, 105(NR)
Biosensors, 612(B)
BioSPECS, profile, 1022(NR)
Biosurfactants, 1059(B)
Biotech draft directive, 108(NR)
Biotechnology, 468(NR), 663(NR), 927(NR), 1016(NR)
Biotechnology forum, 385(NR), 928(NR)
Bird, toxic, 12(P)
Bisset, Norman Grainger, 816(O)
Blood liquefaction, 116(L), 296(L)
BOC,
  new gas plant, 559(NR)
  profile, 840(TP)
BP, Bitor sale, 1021(NR)
BP Chemicals,
  job cuts, 281(NR)
  plant closure, 184(NR)
BP Nutrition sell-offs, 662(NR)
British Association meeting, 841(TP)
British Technology group, 1017(NR), 1018(NR)
Business in Europe, 190(NR)

Cahn, R. W., articles, 695(B)
Calgon sale, 662(NR)
Cancer drug, 847(P)
Cannizzaro, 140(B)
Cantab, flotation, 854(NR)
Carbohydrate fuels, 28(L), 198(L), 296(L), 674(L)
Carbohydrates, 696(B)
Carbon allotropes, 297(L), 574(NR)
Carbon nitride, 848(P)
Carbon tetrachloride, 28(L)
Carcinogenesis, 425(B)
Carcinogens, 100(TP), 240(B)
Castleford incident, 15(NR)
Caustic soda, 368(TP)
CBI,
  innovations report, 183(NR)
  white paper comment, 742(NR)
CD-ROM, organic compounds, 976(B)
Cefic assembly, 661(NR)
Celltech,
  Hoffman-La Roche deal, 930(NR)
  share sale, 1016(NR)
Centocor, Wellcome alliance, 930(NR)
CFC control, 18(NR), 741(NR)
Chaos, 611(B), 804(B)
Chatterji, Deb, 840(TP)
Chemac report, 949(C), 1030(L)
Chemical bonds, 328(B)
Chemical delivery systems, 462(P)
Chemical production figures, 852(NR)
Chemical weapons, 584
Chemical Weapons Convention, 103(NR), 283(NR)
Chemistry in Britain, Sept cover, 1029(L)
Chemistry sets, 1005(TP)
China, toxic waste riots, 928(NR)
Chinese herbal drugs, 140(B)
Chinese medicine, 838(TP), 1030(L)
Chiral synthesis, 973(B), 974(B), 1053
Chlorine, 5(TP)
CIA,
  biotechnology forum, 928(NR)
  chemical business outlook, 103(NR)
  health and safety, 398(L)
  Investment conference, 383(NR)
  investment survey, 379(NR)
  responsible care, 269(TP)
  Socsa formation, 468(NR)
Ciba,
  Grimsby site, 661(NR)
  profits, 470(NR), 854(NR)
Cindu chemicals, naphthalene plant, 465(NR)
Climate modelling, 696(B)
Clinical biochemistry, 312, 573(L)
Clinton administration, 176(TP)
CO as messenger molecule, 556(P)
CO_2 fixation, 297(L)
CO_2 emissions, 180(P), 190(NR), 385(NR), 467(NR), 670(NR)
Coalite, NRA action, 18(NR)
Coatings, 892(B)
Combustion at surfaces, 34
Composites, 12(P)
Computer designed chemicals, 460(P)
Computerised control, 385(NR)
Computing for scientists, 804(B)
Conducting polymers, 967
Contaminated land, 959
Control of chemicals, 802(B)
Coordination chemistry, 973(B)
Copper biochemistry, 695(B)
COSHH amendment, 109(NR)
Courtaulds,
  Hoechst fibres deal, 560(NR)
  profile, 8(TP)
Croatia, pollution, 185(NR)
Croda Kerr, Monnex purchase, 283(NR)
Crown ethers, 974(B)
Crystallography, 892(B)
Cyanobacteria, 278(P)
Cyclodextrins, 28(L)
Cyclops, 187(NR)
Cytec spin-off, 927(NR)

Dambusters, 728(TP)
Danish HCFC bans, 1020(NR)
Data protection, 691
Davis, David, 1007(TP)
Degradable plastics, 178(P), 466(NR)
Degree courses, 129
Diabetes treatment, 98(TP)
Dilatant colloids, 731(P), 1030(L)
Dioxins, 140(B), 198(L)
Distance learning, 768
Djerassi, C., autobiography, 695(B)
DNA mismatches, 484
DNA profiling, 178(P), 419
DNA sequence alteration, 202
Dow Chemical
  new thermoplastics, 462(P)
  reorganisation, 104(NR)
Drilling mud, 383(NR)
Drug crime prevention, 415
Drug delivery, 10(P)
Drug licensing, 472(NR)
Drug prices, 665(NR)
Drug trade legislation, 20(NR)
Drugs, natural 327(B)
Drugs, controlled delivery, 425(B)
DTI,
  innovations report, 183(NR)
  SAIS scheme, 383(NR)
DuPont Nylon job losses, 927(NR)
DuPont, plant purchase, 104(NR)
Dyes, 611(B)

Eastman-Kodak split, 661(NR), 852(NR)
EC environment policy, 290(NR), 1020(NR)
EC legislation, 17(NR)
ECMRA, Madrid, 1009(TP)
ECO survey, 108(NR)
Economy, 851(NR)
Ecotoxicology, 1059(B)
Education, 837(TP), 1029(L), 1018(NR)
EELS, 41
Electrochemistry, 1059(B)
Electronic data, 274(TP)
Electronic mail, 28(L)
Electron surface scattering, 41
Elf Sanofi, YSL merger, 183(NR)
Eli Lilly, job cuts, 1019(NR)
Employment in France, 95(TP), 396(L)
EMS-Dottikon explosion, 740(NR)
Energy programmes, EC, 744(NR)
Energy resources, 518(B)
English China Clays, Calgon purchase, 662(NR)
Enimont break-up, 738(NR)
Environment,
  agency, 21(NR)
  and industry, 695(B)
  EC policy, 290(NR), 1020(NR)
  government policy, 105(NR)
  World Industry Council, 928(NR)
Environment and Health Institute, 741(NR)
Environmental convention, 286(NR)
Enzymes in feedstuff, 936(NR)
European chemist registration, 752(L)
Exhaust emissions, 187(NR)
Expert witness fees, 866(L)
Explosion, fertiliser plant, 928(NR)

Faraday centres, 107(NR), 188(NR)
Fats in food, 482(L)
FDA drug approvals, 470(NR)
Feruzzi, rescue plan, 1015(NR)
Fine chemicals, 239(B)
Fire, 517(B)
Fireworks, 277(P)
Fisons,
  abandons Tipredane, 381(NR)
  new labs, 927(NR)
  profits, 852(NR)
  sell-offs, 20(NR), 104(NR)
  Tilade allegations, 1016(NR)
Flame-proofing regulations, 1020(NR)
Floral pigments, 875
Fluorine chemistry, 696(B)
Fluoropolymers, 10(P)
Flu virus inhibitor, 561(NR)
Food,
  additives, 384(NR), 743(NR)
  and cancer, 973(B)
  free radicals, 210
  irradiation, 674(L)
  legislation, 112(NR)
  safety, 140(B), 180(P)
  science, 242(B)
  taints, 1060(B)
Forensic registration, 482(L)
Forensic science,
  analysing evidence, 408
  conference, 463(P)
  DNA profiling, 419
  drug crime precention, 415
  forensic toxicology, 296(L), 405
  House of Lords report, 560(NR)
  inquiry, 283(NR), 465(NR)
  royal commission report, 662(NR)
  scanning electron microscopy, 413
  special issue, 405
Framework 4, 22(NR), 469(NR), 564(NR)
Framework funds, 108(NR)
Free radicals, 1012(P), 1060(B)
Free radicals in food, 210
Free radical reactions, 53(B)
FT-ICR/MS, 611(B)
Funding young researchers, 385(NR)

Gas hydrates, 375(P)
GEC Marconi Ga-As plant, 184(NR)
Genetically engineered synthesis, 687
Genetically modified organisms, 385(NR), 936(NR)
Giachardi, David, 8(TP)
Gibberelic acid, 463(P)
Glaxo,
  chairman resigns, 285(NR)
  FDA warning, 286(NR)
  OTC drugs, 186(NR)
  profits, 852(NR)
  reorganisation, 929(NR)
  SmithKline Beecham patent row, 20(NR), 470(NR)
  suit against Novopharm, 854(NR), 930(NR)
  Wellcome, Warner Lambert OTC link, 740(NR)
GNVQs, 729(TP)
Gold deposits, 734(P)
Government lab job cuts, 1018(NR)
Graduate recruitment, 93(TP), 853(NR)
Green, Michael, 705(O)
Greenpeace, ICI prosecution, 466(NR)

Halon bank, 287(NR)
Hanson Industries, buys Quantum Chemical, 663(NR)
Hazard, reaction, 481(L), 867(L)
Hazardous waste, 460(P)
HCFC phasing out, 666(NR), 1020(NR)
Health and safety, 28(L), 100(TP), 109(NR), 196(L), 328(B), 611(B), 677
  Irish review, 927(NR)
Herbal remedies, 178(P)
Herbicides, 425(B)
Hermaphrodite fish, 481(L), 674(L)
Heterocyclics, 54(B)
Hickson and Welch,
  Castleford report, 15(NR)
  fined, 739(NR)
  HSE prosecution, 465(NR)
Higher education, 299(C), 1018(NR)
History of chemistry, 53(B), 891(B)
History of science, 370(TP), 518(B), 801(B), 973(B)
Hoechst,
  accidents, 380(NR)
  Courtaulds fibres deal, 560(NR)
  profits, 16(NR), 379(NR), 851(NR)
  Schering deal, 559(NR), 737(NR)
  South America, 554(TP)
Hoffman-La Roche, Celltech deal, 930(NR)
Holliday Chemical Holdings,
  profits, 853(NR)
  share flotation, 282(NR)
Holt, Paul Frederic, 251(O)
Hormones in livestock, 290(NR), 564(NR), 743(NR)
Hünig's base, 1042
Huntsman Corporation, Texaco Chemical purchase, 851(NR)
Hutchinson, David, 437(O)
Hydrocarbon dendrimer, 460(P)

ICI,
  Barr, settlement, 285(NR)
  BASF exchange, 185(NR)
  electricity deal, 185(NR)
  Greenpeace prosecution, 466(NR)
  herbicide, 10(P)
  Monnex sale, 283(NR)
  Monsanto dispute, 17(NR)
  new fungicide, 17(NR)
  new subsidiary, 15(NR)
  profits, 468(NR), 737(NR), 1016(NR)
  Zeneca demerger, 104(NR), 281(NR), 470(NR)
Illuminated manuscripts, 118
Image,
  chemistry, 482(L), 945(L)
  industry, 379(NR)
  pharmaceuticals, 367(TP)
  science, 853(NR)
Immunosupressants, 659(P)
Inch, Tom, profile, 725(TP)
Incinerator, new ReChem, 18(NR)
Incinerators, planned, 18(NR)
Inclusion compounds, 132
Industrial chemistry,
  chiral synthesis, 1053
  drug process development, 1037
  Loop reactor process, 1050
  oxalyl chloride, 1046
  process development, 1035
  selective reagents, 1042
  special issue, 1035
Ingold, Christopher Kelk, 867(L), 880
Inorganic chemistry, 328(B)
Inorganic materials, 891(B)
Inorganic ring systems, 517(B)
Institut Merieux, Rhône-Poulenc merger, 930(NR)
Interstellar chemistry, 680
Ionic strength, 1033(C)
Irving, Harry, 982(O)

Japanese industry, 1018(NR)
Japanese research, 801(B)
Japanese science, 553(TP)
Jet fuels, 760, 947(L)

Kekulé, August, 126, 974(B)
Kirk, David Neville, 437(O)
Kodak-Eastman split, 661(NR), 852(NR)

Laboratory reports, 518(B)
Laevoglucosan, 278(P)
Lancaster Synthesis new site 184(NR)
Landowner Liquid Fertilisers, explosion, 928(NR)
Lawter Products, explosion, 853(NR)
Lecture-demonstrations, 656(TP), 868(L)
Leslie, May Sybil, 206, 573(L)
Lewis, David Thomas, 250(O)
Light, 425(B)
Limited list drugs, 186(NR)
Lipids, 696(B)
Liquid crystal polymers, 425(B)
Livestock fattening, 17(NR)
Llewelyn-Jones, prosecution, 559(NR)
Loop reactor process, 1050
Lorenzo's oil, 175(TP)
Loschmidt, Josef 126

Magic bullet, 770
Malaria drug, 923(P)
Manoplax,
  warning, 470(NR)
  withdrawn, 737(NR)
Marine sponge drug, 556(P)
Mass spectrometry, 54(B)
Materials science, 139(B)
Mechanisms, organic, 696(B)
Medco sale, 740(NR), 1019(NR)
Medeva,
  profits, 285(NR), 854(NR)
  Ribosepharm acquisition, 381(NR)
  shares fall, 738(NR), 1015(NR)
Media fellowships, 173(TP)
Medicinal chemistry, 974(B)
Medicine, natural, 327(B)
Medicines Information Bill, 186(NR), 285(NR), 465(NR)

Key

B—Book review
C—Controversies
L—Letter
NR—News review
O—Obituary
P—Perspective
TP—Talking point

Merck, Medco acquisition, 740(NR), 1019(NR)
Metal extraction, 802(B)
Methyl bromide ban, 382(NR)
Microelectrodes, 764
Microwave irradiation, 848(P)
Miller, Christina C., 492
Mineral water, 855(NR)
Mineralisation, 374(P)
Miticide, new, 17(NR)
Molecular design, 54(B)
Molecular logic, 923(P)
Molecular modelling software, 328(B)
Molecular reaction dynamics, 308
Molecular recognition, 1059(B)
Monoclonal antibodies, 770
Monsanto, ICI dispute, 17(NR)
Montreal protocol, 18(NR)
Mortality study, 677, 947(L)
MRI, 597
MTM,
  investigation, 465(NR)
  share prices, 104(NR)
Muir, Geoffrey, 626(O), 752(L)
Myoglobin filters, 375(P)

National Historic Chemical Landmarks Program, 929(NR)
National Power lab donation, 663(NR)
Natural product synthesis, 328(B), 687, 891(B)
Nayler, John, 531(O)
Near-infrared spectroscopy, 658(P)
Nerc annual report, 106(NR)
Nerve cell transplants, 924(P)
Neste, Statoil merger, 661(NR)
Neural networks, 495
NHS research programme, 742(NR)
Nitroglycerin, 734(P)
NMR,
  clinical, 597
  in solids, 601
  macromolecular, 605
  special issue, 589
  structure determination, 593
Nobel, Akzo merger, 1015(NR)
Nobel prize-winners, 917(TP), 1006(TP)
Nomenclature, 296(L), 574(L), 867(L)
Non-animal testing, 917(TP)
Norman, Richard, 815(O)
Norsk Hydro, profits, 380(NR), 928(NR)
Novo Nordisk profile, 19(NR)
Novopharm, Glaxo suit, 854(NR), 930(NR)
NRA
  annual report, 933(NR)
  civil action against Coalite, 18(NR)
  policy launch, 187(NR)
  R&D, 467(NR)
Nucleoside synthesis, 54(B)

Obituaries, 70, 152, 250, 251, 340, 341, 437, 531, 625, 626, 705, 815, 816, 982, 1068
Organic compounds, 976(B)
Organic peroxides, 892(B)
Organic superconductors, 801(B)
Organic synthesis, 53(B)
Organic synthesis reagents, 327(B)
Organochlorines, 396(L)
Organofluorines, 215
Organometallics, 140(B)
Organophosphorus compounds, 239(B)
Origin of elements, 1059(B)
OST,
  commons report, 106(NR)
  research report, 383(NR)
OTC drugs, 20(NR), 186(NR)
Oxalyl chloride, 1046
Oxygenated petrol, 382(NR)
Ozone depletion, 466(NR)

Pacific sponge, 556(P)
Packaging recycling, 933(NR), 1021(NR)
Packaging waste, 562(NR), 670(NR), 1021(NR)
Paper treatment, 116(L)
Parliamentary Link scheme, 727(TP)
Patents, 489
PCB study, 466(NR)
Perfluorocarbons, 658(P)
Pesticides, 112(NR), 974(B)
Pharmaceutical markets, 561(NR)
Pharmaceutical Price Regulation Scheme, 853(NR)
Pharmaceutical strategies, 653(TP)
Phenolic compounds, 802(B)
Photocatalysis, 481(L)
Photochemistry, 240(B), 802(B)
Photoconducting polymers, 98(TP)
Photodynamic therapy, 376(P), 955
Physical chemistry, 1060(B)
Physical chemistry software, 518(B)
Physical organic chemistry, 328(B)
Physics and fine art, 240(B)
Pigment identification, 118
Plant patents, 108(NR)
Poisons, 327(NR)
Pollard, Mark, profile, 174(TP)
Pollution, 684
  IPC directive, 1020(NR)
  prevention, 892(B)
  prosecutions, 467(NR)
Polyarenes, 54(B)
Polymerisation, 732(P)
Polymers, 239(B), 612(B), 804(B)
  chromatography, 891(B)
  flammability, 556(P)
  recycling, 277(P), 696(B), 847(P)
  sensors, 967
Polysiloxane coatings, 731(P)
Postgrad training, 1017(NR)
PowerGen, Orimulsion permission, 741(NR)
Practical chemistry, 871(C)
Pritchett, Eric George Kemp, 251(O)
Process development, 1035, 1037
Procordia split, 739(NR)
Procter and Gamble, closures, 738(NR)
Protein conformation, 139(B)
Protein monolayers, 376(P)
PSC report, 283(NR)
Pyke, Magnus, 341(O)
Pyrotechnics, 277(P)

Qualiphar, expansion, 1019(NR)
Quantum Chemical, Hansom Industries buy-out, 663(NR)
Quantum chemistry, 30(L)
Quantum theory, 612(B)
Quotes on science, 239(B)

R&D, 41
  government review, 929(NR)
  investment, 383(NR)
  spending, 185(NR), 560(NR)
Radioactive waste, 469(NR)
Radiopharmaceuticals, 139(B)
Raman microscopy, 118
ReChem,
  court case, 1021(NR)
  incineration plant, 18(NR), 741(NR)
Redundancy, 137
Rees, Charles, 654(TP)
Reppe, Walter, 38
Research council funding, 742(NR)
Research funding, 188(NR)
Research ratings, 196(L), 297(L), 398(L), 482(L)
Responsible care, 269(TP), 666(NR)
Rhône-Poulenc,
  Institut Merieux merger, 930(NR)
  pollution fine, 187(NR)
  privatisation, 1015(NR)
  profits, 284(NR)
  share offer, 184(NR)
  Snia deal, 662(NR)
Richmond, Mark, Glaxo appointment, 929(NR)
Risk analysis, 139(B)
Rothamsted Experimental Station, 755, 1029(L)
RSC,
  annual congress, 453(TP), 674(L)
  Benevolent Fund, 888
  journals, 843(TP)
  Parliamentary Link scheme, 727(TP)
  policies, 654(TP), 1030(L)
  role, 945(L)
  science recommendations, 929(NR)

Sacconi, Luigi, 626(O)
Safety, 297(L)
Salford Ultrafine, new site, 663(NR)
Sasol-AECI merger, 662(NR)
Scanning electron microscopy, 413
Schering,
  Betaseron approval, 740(NR)
  Hoechst venture, 559(NR), 737(NR)
Science budget, 282(NR)
Science policy, 15(NR)
Self assembly, 300
Separation chemistry, 1060(B)
Serc,
  chemistry committee, 96(TP)
  funding, 106(NR), 383(NR)
  postgrad study, 106(NR)
Sheehan, John C., 152(O)
Shell sell-off, 661(NR)
Shetland oil spill, 105(NR)
Silicon grease, 848(P)
Silicon wafers, 732(P)
Site-directed mutagenesis, 202
Smart awards, 21(NR)
Smith, Ernest Lester, 437(O)
SmithKline Beecham,
  Glaxo patent dispute, 20(NR), 470(NR)
  Harlow move, 1019(NR)
  new lab, 1015(NR)
  profits, 285(NR)
  Tagamet OTC, 740(NR)
Snia, Rhône-Poulenc deal, 662(NR)
Software, 612(B), 974(B)
Solid state chemistry, 801(B)
Solid state NMR, 139(B)
Solomon, Susan, 551(TP)
Solvent emissions charter, 466(NR)
Sound sensitisation, 198(L)
Speciality chemicals, 518(B)
SPECS, profile, 1022(NR)
Spider pheromones, 1012(P)
Statoil-Neste merger, 661(NR)
Stereochemistry, 240(B)
Suddaby, Donald, 175(TP), 1064(O)
Supercritical fluids, 499
Supplementary protection certificate, 665(NR)
Surface analysis, 41
Surface combustion, 34
Surfactants, 239(B), 327(B), 611(B)
Suryanarayana, Chittari Venkata, 531(O)
Sutton, Leslie Ernest, 625(O)
Symmetry, 802(B)
Synchrotron radiation, 517(B)

Teacher prosecuted, 559(NR)
Teaching, primary, 49, 866(L)
Temporary staff, 776
Tertiary education, 129, 188(NR)
Tetrahydroanthraquinone, 659(P)
Texaco Chemical, sale, 851(NR)
Thermodynamics, 698(B)
Thermoplastics, 462(P)
Tioxide Canada, pollution offences, 105(NR)
Tipredane abandoned, 381(NR)
Titanium dioxide, 503, 752(L), 947(L)
Total quality, 517(B)
Toxic waste riots, 928(NR)
Toxin from bird, 12(P)
Transfermium elements, 664(NR)
Transuranium elements, 612(B)
Tunable diode lasers, 883
Tyre pyrolysis, 196(L)
Tyre recycling, 924(P)
Tyrosinaemia treatment, 10(TP)

UFC research ratings, 107(NR)
Ultramarine pigment, 952
UNEP-UK future, 187(NR)
University of Aberdeen, 200 year anniversary, 964
University ratings, 107(NR)
Upjohn court case, 665(NR)

Vaccine compensation, 561(NR)
Virtual reality, 455(TP)
Volatiles emissions, 670(NR)

Warner Lambert,
  suspensions, 854(NR)
  Wellcome, Glaxo OTC link, 740(NR)
Warren Spring closure, 559(NR)
Waste disposal, 30(L)
Waste incineration, 517(B), 562(NR)
Waste transport, 190(NR)
Water in food, 327(B)
Wellcome,
  Centocor alliance, 930(NR)
  Glaxo, Warner Lambert OTC link, 740(NR)
  profits, 1019(NR)
  share price, 381(NR)
White paper, 15(NR), 106(NR), 365(TP), 549(TP), 668(NR)
Wine labelling, 743(NR)
Women academics, 663(NR)
Women chemists, 1010(TP)
Wood, Eric, 531(O), 752(L)
World chemical industry forum, 454(TP)

Yamanouchi, profile, 931(NR)
Yorkshire Chemicals expansion, 183(NR)
Young, Leslie, 705(O)
Yves Saint Laurent, Elf Sanofi merger, 183(NR)

Zappi, Enrique Vincente, 305
Zeneca,
  drug development, 10(P)
  ICI demerger, 15(NR), 104(NR), 281(NR), 470(NR)
  profits, 737(NR)
  reorganisation, 285(NR)

Authors

Angoh, Gaë, 1046
Archer, David, 49
Aruoma, Okezie, 210
Ashmore, A. D., 729(TP)

Bader, Alfred, 126
Bartle, Keith, 499
Bell, Jimmy D., 597
Bell, Andrew J., 308
Ben, Stephen, 727(TP)
Berlande, Jacques, 308
Best, Stephen, 118
Blackden, Ben, 776
Braithwaite, Malcolm J., 1042
Brill, Thomas, 34
Brown, Stanley B., 955
Brown, Tom, 484
Butler, Anthony R., 952

Carey, Joe, 1053
Carlyle, Anastasia, 888
Cassidy, John F., 764
Chalmers, Robert A., 492
Chapman, Steven, 202
Clark, Robin, 118
Cleminson, Andrew, 768
Clifford, Tony, 499
Coleman, Michael M., 760

Daniels, Marcus, 118
Drillsma, Barbara, 1005(TP)

Elliott, Henry, 129

Farago, Margaret, 1010(TP)
Feeney, James, 605
Féher, Miklós, 883
Foley, M. Barry, 764
Frey, Monty, 843(TP)

Gash, Rosslyn, 952
Geddes, Ken, 1050
Gittins, Len, 684
Gunsell, Jill, 691

Hanson, Jim, 871
Harris, Kenneth D. M., 132
Harris, Robin K., 601
Haslam, Edwin, 875
Hayes, Jerome F., 1037
Henman, Barry A., 677
Hoppé, Jack, 871
Howarth, Oliver, 589
Hunter, W. N., 484
Hunter, William J., 677

Jackson, Arthur, 1046
Jones, Sally, 554(TP)
Jones, Stephen T., 419
Judin, Vesa P. S., 503

Keeler, James, 593
Keeley, Robin H., 412
Ketteman, Claire, 1042

Laird, Trevor, 1035
Leonard, G. A., 484

Ma, Uly, 45
Maccoll, Allan, 880
Martin, Philip A., 883
Menger, Fredric M., 300
Mestdagh, Jean Michel, 308
Milgrom, Lionel, 553(TP), 949(C)
Miller, Arthur L., 312
Mitchell, Michael B., 1037
Monk, C. B., 1033(C)
Morris, Peter J. T., 38
Muir, John, 137
Murray, Robert, 299(C)

Noe, Christian, R., 126

Parker, W. J., 728(TP)
Pidgeon, Robert J., 489
Prichard, Bill, 871

Rae, Ian D., 305
Rayner-Canham, Geoff, 206
Rayner-Canham, Marelene, 206
Reed, Neville, 49
Reid, Graeme, 202
Reynolds, Tim, 173(TP)
Richards, Jeffrey, 299(C)
Richardson, Neville V., 41
Roulston, Joseph E., 770
Rouvray, Dennis, 495
Rowley, Alan G., 959

Sadler, Peter J., 597
Salter, Martin, 408
Schobert, Harold H., 760
Scott, A. Ian, 687
Silvester, Michael, 215
Song, Chunsan, 760
Stevenson, John H., 755

Taylor, Stephen, 680
Thiel, Inge M. E., 305
Thomson, Ronald H., 964
Truscott, T. George, 955

Wallace, Gordon G., 967
Wallace, Raymond, 299(C)
Wiggins, Ken, 408
Wilkinson, Maurice, 1050
Williams, David, 680
Wilson, Bill, 405, 415
Wilson, Jennifer M., 129
Withers, Michael, 275(TP)
Withnall, Robert, 118